Elsevier

Dermatologic Clinics

Volume 22, Issue 2, April 2004, Pages 197-205
Dermatologic Clinics

Complications with the use of botulinum toxin

https://doi.org/10.1016/S0733-8635(03)00122-0Get rights and content

Section snippets

Conditions caused by muscle spasms

Local injections of botulinum toxin type A (Botox) directly into excessively contracting muscles have been successful in treating dystonia, spasticity, and other conditions characterized by inappropriate muscle spasm [16], [17]. Botox is considered a safe therapy for these inappropriate muscle spasms and is generally well tolerated, with adverse effects being typically self-limited [18].

Effects of a localized injection of botulinum toxin to nearby or adjacent muscles are believed to be a result

Resistance to botulinum toxin

The possibility of antibody production with resulting immunoresistance has always been a concern with the use of Botox [26]. Hypersensitivity reactions to the injection of the substance do not occur. The only consequence is that Botox no longer is effective as a treatment. With the original Allergan batch [27], it was recommended that not greater than 100 U be used at treatment sessions that occur at not less than monthly intervals. Antigenicity of a foreign material, however, is almost

Cosmetic use of botulinum toxin

Facial wrinkles are frequently caused by repeated muscle contraction. Botulinum A exotoxin can produce weakness or paralysis of these muscles and offers a novel approach for the treatment of certain facial rhytides. Botulinum toxin type A weakens the overactive underlying muscle contraction, causing a flattening of the facial skin and an improved cosmetic appearance [35]. The effect, although temporary, is extremely popular with patients, has a very low incidence of side effects, and is a

Glabella

The most common complication in treatment of the glabellar complex is ptosis of the upper eyelid. Eyelid ptosis is a significant risk if injections are placed at or under the middle of the eyebrows in the vicinity of the mid-pupillary line. This is cause by diffusion of the toxin through the orbital septum, where it affects the upper eyelid levator muscle. This can occur as early as 48 hours or as late as 7 to 10 days following injection when the aesthetic effect is beginning to appear and can

Brow

The most significant complication of treatment of the frontalis is brow ptosis. Botulinum A exotoxin should not be injected above the middle brow so as to avoid brow ptosis. Injection should also be avoided within 1 cm of the bony superior orbital rim for the same reason. Botox works best in younger female patients (20 to 45 years of age). In some older patients and in some male patients, redundant skin can be created under the brow (pseudoptosis), so such patients should be approached with

Crow's-feet

Reported complications in this area are bruising, diplopia, ectropion, or a drooping lateral lower eyelid and an asymmetric smile caused by injection of zygomaticus major. To avoid these complications, one should inject at least 1 cm outside the bony orbit or 1.5 cm lateral to the lateral canthus, and not inject close to the inferior margin of the zygoma. Just as it is important not to inject too close to the eye, injections should not be placed too far below it or too deep, because the

Nasolabial folds

Some physicians have treated levator labii superioris alaeque nasi to soften the superomedial part of the nasolabial fold. They have used relatively low doses (2 to 3 U of Botox per side) including EMG localization of the site but report unimpressive response. In those individuals who did get softening of the folds, some showed lengthening of the upper lip, which of itself is aging. Initially, several nasolabial injections were given. Although they reduced the nasolabial groove, they also

Injecting the lower face and neck

Many of the muscles in the lower central face, especially those used in facial expression, are also involved in the functions of the mouth and cheeks. An asymmetric smile, biting the inside of a flaccid cheek, or incompetence of the mouth manifest by drooling and dribbling are possible complications of the overly enthusiastic use of Botox in the lower face. Small doses, however, can be used satisfactorily (eg, into mentalis, nasalis, and levator labii superioris alaeque nasi). More recently

Complications in treating hyperhidrosis

Chronically sweaty palms are uncomfortable and socially debilitating. Superficial injection of botulinum toxin can provide dramatic relief from this disorder. Injections should be at the level of the superficial dermis and no deeper. Given the ability of Botox to diffuse radially in the axillary skin in a 1.5-cm radius, the physician must first identify the surface area of involvement using the starch-iodine test. Intercurrent doses of intradermal botulinum toxin can then be placed spaced at

Treatment of migraine headaches

In a double-blind clinical study of migraine headache treatment conducted by Silberstein et al [45], there were no reported cases of true eyelid ptosis, diplopia, facial nerve or expression problems, keratopathy, or idiosyncratic or allergic reactions attributable to Botox treatment. Two subjects reported transient brow ptosis; other adverse effects were limited to transient local pain and ecchymosis at the injection site [45].

In another double-blind clinical study conducted by Brin et al [46],

Informed consent

In the informed consent, it must be brought to the patient's attention that Botox has been approved by the FDA as a safe and effective therapy since 1989 for use in blepharospasm, strabismus, and hemifacial spasm and since 1992 for glabellar lines. The National Institutes of Health consensus conference of 1990 also included Botox as safe and effective therapy for the treatment of adductor spasmodic dysphonia, oromandibular dystonia, and cervical dystonia. The treatment of facial wrinkles other

First page preview

First page preview
Click to open first page preview

References (46)

  • A.W Klein et al.

    Electromyographic guidance in injecting botulinum toxin

    Dermatol Surg

    (1998)
  • W.J Binder et al.

    Treatment of hyperfunctional lines of the face with botulinum toxin A

    Dermatol Surg

    (1998)
  • A.W Klein et al.

    Botulinum toxin: beyond cosmesis

    Arch Dermatol

    (2000)
  • C Lamanns

    The most poisonous poison

    Science

    (1969)
  • M Keen et al.

    Botulinum toxin A therapy for hyperkinetic facial lines: results of a double-blind, placebo-controlled study

    Plast Reconstr Surg

    (1994)
  • E Somers et al.

    Clostridium botulinum type A, B, C1 and E produce proteins with or without hemagglutinating activity: Do they share common amino acid sequences and genes?

    J Protein Chem

    (1991)
  • G Sakaguchi

    Clostridium botulinum toxins

    Pharmacol Ther

    (1983)
  • P.F Bonventre et al.

    Physiology of toxin production by Clostridium botulinum types A and B. III. Effect of pH and temperature during incubation on growth, autolysis, and toxin production

    Appl Microbiol

    (1959)
  • C.T Townsend et al.

    Inhibition of the growth of Clostridium botulinum by acidification

    Food Res

    (1954)
  • R.A Baffi et al.

    Quality control issues in the analysis of lyophilized proteins

    Dev Biol (Basel)

    (1991)
  • Borodic G.E., Ferranter R. Orbicularis muscle histology after repetitive injections of botulinum A toxin. Presented at...
  • R.R Sloop et al.

    Human response to botulinum toxin injection: type B compared with type A

    Neurology

    (1999)
  • J Jankovic et al.

    Botulinum toxin: historical perspective and potential new indications

    Muscle Nerve

    (1997)
  • Cited by (0)

    View full text